Safety and Efficacy of Using the Endodontic Self Adjusting File - SAF for Root Canal Treatment
1 other identifier
interventional
100
1 country
1
Brief Summary
The study's primary goal is to assess the safety of the SAF (Self Adjusting File) device for root canal treatments. The study's secondary goal is to evaluate the effectiveness of the SAF device for root canal treatments
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 4, 2007
CompletedFirst Posted
Study publicly available on registry
July 6, 2007
CompletedJuly 11, 2007
July 1, 2007
July 4, 2007
July 10, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Treatment related operative and postoperative major complications.
One year.
Secondary Outcomes (1)
Healing of pariapical leasions as a result of the endodontic treatment.
One year.
Interventions
Eligibility Criteria
You may qualify if:
- Subjects is 18 years or older
- Subject has one or more teeth that have to go through a root canal treatment
- Roots are fully formed and with a mature apex
- At least one of the roots to be treated has periapical radiolucency with a diameter of 2-6mm and a PAI score of 4 or 5
- Subject had signed the informed consent form
You may not qualify if:
- Previous root canal filling
- Roots with abnormal root canal anatomy
- Roots for which a good quality periapical radiographic image cannot be produced
- Un-restorable teeth
- Significant periodontal pockets
- Patients who are pregnant or breast-feeding
- Uncontrolled systemic hypertension
- Severe uncontrolled Diabetes Mellitus
- Current steroid therapy in excess of prednisone 5 mg/day
- HIV positive patients
- Hepatitis
- Chronic renal failure
- Hematological disease (malignancy, severe anemia)
- Osteoporosis, receiving biphosphonates
- Post head and neck irradiation treatment
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ReDent Novalead
Study Sites (1)
Tel Aviv Souraski Medical Center
Tel Aviv, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Amnon Singer, DMD
Redent Nova Ltd.
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
July 4, 2007
First Posted
July 6, 2007
Last Updated
July 11, 2007
Record last verified: 2007-07